Condition
Malignant Neoplasm of Lung
Total Trials
5
Recruiting
0
Active
2
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (2)
P 2 (1)
Trial Status
Active Not Recruiting2
Completed1
Terminated1
Unknown1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05853575Phase 2Active Not Recruiting
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
NCT05375994Phase 1Active Not Recruiting
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
NCT04975256Phase 1Terminated
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
NCT02013063UnknownPrimary
Single Pulmonary Nodule Investigation
NCT01451359Not ApplicableCompletedPrimary
Endobronchial Valves in Persistent Air Leak
Showing all 5 trials